28 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement Study

Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup Prosthesis Study (28mm)

The study is designed to evaluate artificial hips with a 28 mm ceramic head and a ceramic liner to determine whether they perform as well as artificial hips with a 28 mm ceramic head and a polyethylene liner.

Study Overview

• Status: Completed
• Conditions: Joint Diseases
• Intervention / Treatment: Device: 28 mm ceramic head on ceramic acetabular liner.; Device: 28 mm ceramic head on polyethylene liner

Detailed Description

Total Hip Arthroplasty (THA) is the surgical reconstruction of the hip joint through replacement of the femoral head and the acetabular articulating surfaces with fixed prosthetic devices. The goals of THA are relief from pain, restoration of function, and correction of deformity. THA is one of the most common adult reconstructive procedures. Over the past 25 years, patients who have needed to have their hip joint replaced, either due to trauma or arthritic disease, typically have had their hip joint bone articular surfaces replaced with a metal hip stem, metal ball head (either stainless steel or chrome cobalt) and a plastic acetabular cup (metal/metal/plastic). While the basic device has remained essentially unchanged over that period, technological advancements in implant designs and materials, and improvements in surgical technique and instrumentation have made THA one of the most durable and successful procedures in medicine. Reproducible, high-quality, short-term and mid-term results are attained regularly, and total hip replacements commonly last 10 to 15 years and longer. The success of this procedure has allowed its expansion into a wider, and often younger and more active population.

In spite of the improvements in THA, little change has occurred for the acetabular cup liner, which is usually made out of Ultra High Molecular Weight Polyethylene plastic (UHMWPe). Because it is plastic and inherently soft and somewhat pliable under load, the cup's articular surface must inevitability wear and produce debris. This biologic response is now thought to be a significant contributor to prosthetic component loosening, a primary failure mode of THR. UHMWPe also degrades with time in the body. As concerns about polyethylene wear and the associated untoward effects of the generated wear debris, and as THA continues to be used in younger and higher-demand patients with increasing life expectancies, interest in ceramic on ceramic total hip prosthesis has been renewed.

An alumina ceramic-on-ceramic acetabular coupling has been employed as an alternative to metal/polyethylene couplings. This ceramic-on-ceramic coupling has many advantages, including the elimination of polyethylene from the device system, wear rates that are appreciably less than those experienced with metal/polyethylene couplings and reduced biologic reactivity. The potential benefits of an alumina ceramic/ceramic bearing are significant.

• Study Type: Interventional
• Enrollment (Actual): 264
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Colorado
    • Denver, Colorado, United States, 80210
      • Colorado Joint Replacement
  • Ohio
    • Columbus, Ohio, United States, 43213
      • Cardinal Orthopaedic Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Non-inflammatory degenerative joint disease. Composite diagnoses of NIDJD include osteoarthritis, avascular necrosis, post-traumatic arthritis, slipped capital femoral epiphysis (SCFE), fracture of the pelvis, and developmental dysplasia.
• X-ray evaluation confirms the presence of NIDJD
• Femoral and acetabular bone stock is sufficient, regarding strength and shape, and is suitable to receive the implants.
• Individuals 20 to 75 years of age at the time of surgery
• Patients with a previous total hip replacement of the contralateral leg who have a pain rating of none or slight and who are at least one year post arthroplasty are eligible for participation in the study.
• Harris Hip Score of 70 or lower
• Pain at least Moderate

Exclusion Criteria:

• Presence of a previous prosthetic hip replacement device (any type, including surface replacement arthroplasty, endoprosthesis, etc.) in the hip joint to be operated.
• Previous Girdlestone procedure (resection arthroplasty) or surgical fusion of the hip to be operated.
• Acute femoral neck fracture.
• Above knee amputation of the contralateral and/or ipsilateral leg.
• Patients with bilateral degenerative joint disease requiring staged or simultaneous hip replacements.
• Patients with an existing total hip arthroplasty in the contralateral hip with a Harris Hip pain rating of mild, moderate, marked or totally disabled.
• Patients who have undergone total hip arthroplasties in their contralateral hips within the past 12 months.
• Patients with a known allergy to metal (e.g. jewelry).
• Skeletally immature patients (tibial and femoral epiphyses are not closed). Evidence of active infections that may spread to other areas of the body (e.g., osteomyelitis, pyogenic infection of the hip joint, overt infection, urinary tract infection, etc.).
• The presence of highly communicable disease or diseases that may limit follow-up (e.g., immuno-compromised conditions, hepatitis, active tuberculosis, etc.).
• Presence of known metastatic or neoplastic disease.
• Significant neurologic or musculoskeletal disorders or disease that may adversely affect gait or weight bearing, (e.g., muscular dystrophy, multiple sclerosis).
• Conditions that may interfere with the total hip arthroplasty's survival or outcome, (e.g., Paget's disease, Charcot's disease).
• Any patient believed to be unwilling or unable to comply with a rehabilitation program for a cementless total hip replacement or who indicates difficulty or inability to return for follow-up visits prescribed by the study protocol.
• Patient is known to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser.
• Any systemic steroid therapy, excluding inhalers, within three months prior to surgery.
• Patients carrying the diagnosis of inflammatory degenerative arthritis (IDJD) to include the following composite diagnoses: rheumatoid arthritis, systemic lupus erythematosus, pigmented villonodular synovitis, juvenile rheumatory arthritis and other arthritic processes of inflammatory or autoimmune etiology.
• Patients requiring structural bone grafts in order to support the prosthetic component(s) or to shape the bone to receive the implant(s).
• Patients who refuse to provide consent to participate in the clinical investigation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Delta Ceramax Ceramic-on-Ceramic Acetabular Cup System; Total hip replacement with a 28 mm ceramic head and liner.	Device: 28 mm ceramic head on ceramic acetabular liner.; Total hip replacement with 28 mm ceramic head on ceramic liner articulation; Other Names: Delta Ceramax™ 28 mm Ceramic-on-Ceramic Acetabular Cup
Active Comparator: Pinnacle™ Acetabular Cup with Marathon® Polyethylene; Total hip replacement with 28 mm ceramic head with a polyethylene liner.	Device: 28 mm ceramic head on polyethylene liner; Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.; Other Names: Detla Ceramax 28 mm ceramic femoral head and Marathon polyethylene liner.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Harris Hip Total Score	The Harris Hip scoring system assigns a numeric value to responses from patients and assessments made by a surgeon. Scores ranges from a minimum of zero to a maximum score of 100. A score of 91-100 is excellent, 81-90 is good, 71-80 is fair, 70 or below is poor. The patient records the following: pain level, need for assistance when walking, presence of a limp, distance able to walk, ability to put on shoes and socks, climb stairs, use public transportation and the length of time one is able to comfortably sit in a chair are all scored.	The Harris Hip Total Score evaluation took place at 6 weeks, 6 months, 12 months, and a final evaluation at 24 months or greater (up to 96 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complication Rates	Complication Rates are reported by each type of complication (adverse events/AEs) in the Adverse Events Tab	The Complication Rates were evaluated at 6 weeks, 6 months, 12 months, and a final evaluation at 24 months or greater (up to 96 months)

Collaborators and Investigators

• Sponsor: DePuy Orthopaedics
• Investigators: Principal Investigator: Joel Politi, MD, Cardinal Orthopaedic Institute; Principal Investigator: Douglas Dennis, MD, Colorado Joint Replacement

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2003
• Primary Completion (Actual): January 5, 2012
• Study Completion (Actual): January 5, 2012

Study Registration Dates

• First Submitted: September 13, 2005
• First Submitted That Met QC Criteria: September 13, 2005
• First Posted (Estimated): September 21, 2005

Study Record Updates

• Last Update Posted (Actual): November 7, 2023
• Last Update Submitted That Met QC Criteria: November 2, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Joint Diseases; Non-Inflammatory Degenerative Joint Disease
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Joint Diseases
• Other Study ID Numbers: COC 28 mm